Increasing MAT Engagement With Financial Incentives
Key facts
- Who runs it
- Rowan University
- Where
- Camden, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 92 people enrolled
- Started
- 27 Jan 2020
- Ended
- 1 Nov 2024
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Contingency management
- Record updated
- 4 April 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Participants at least 18 years of age
- Participants must be newly enrolled in the Bridge program in the Cooper University ED, with their first clinic appointment scheduled to take place at the Cooper Outreach Clinic within one week of enrollment
- All subjects must be in good physical health as determined by a physical examination and premenopausal women will have a pregnancy test on the day of the study to rule out pregnancy
Who cannot take part
- Participants who demonstrate contraindication with Suboxone treatment or who are currently or have recently used other medication-assisted therapies for opioid use disorder
- Participants who are currently pregnant or breastfeeding or have been diagnosed with a DSM-5 psychiatric condition that might interfere with treatment delivery (e.g., uncontrolled schizophrenia, bipolar disorder, dementia)
- Participants who are non-English speaking or cannot otherwise provide valid informed consent
- Individuals who are unable to complete the survey assessments, due to literacy or visual impairments
- The participant will not be a prisoner
Where in United States
- Cooper University HospitalCamden, United States
About the trial
What the trial wants to find out
The increased prevalence of opioid use disorder (OUD) and associated overdoses and adverse events has led to a substantial increase in the number of patients being seen at emergency departments (ED). Thus, the ED may be an ideal location for identifying patients in need of OUD treatment and can serve as the first touch point in the OUD continuum of care to promote medication assisted treatment initiation. Contingency management (CM) is an effective method for promoting treatment initiation and adherence that has not been thoroughly evaluated for this purpose. The primary aim of the current study is to develop and assess the effectiveness, acceptability, and feasibility of a protocol for delivering CM to increase combined buprenorphine + nalaxone (referred to as BUP hereafter) initiation and continuous adherence for OUD in an existing ED "bridge" program (e.g., Bridge plus CM; B+CM) relative to standard care. Secondary objectives include identifying behavioral and neuropsychological correlates to treatment outcomes, including delay discounting, reinforcer demand, and neurological soft signs.
The 2 groups in the trial
- Contingency ManagementTreatment being tested
Participants in this arm of the study will receive financial incentives for attending their buprenorphine appointments and for being clean from other opioids. Participants in this group will also have up to two rides per week paid for to attend bup appointments.
- Standard CareNo study treatment, for comparison
Participants in this group will be treatment as usual and will not receive any incentives for attending their bup appointments or for being opioid abstinent.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Increasing MAT Engagement With Contingency Management Among Individuals With Opioid Use Disorder in an ED Bridge Program
- Publications
- Pragmatic and low-cost contingency management intervention increases buprenorphine treatment engagement: Randomized controlled trial.Experimental and clinical psychopharmacology, 2026
- Record updated
- 4 April 2025